NDA 208083 · Baxter Hlthcare Corp
Clindamycin Phosphate In 0.9% Sodium Chloride
Clindamycin Phosphate · Intravenous
Last checked: Nov 20, 2026Latest source record: Sep 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Apr 20, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
274
66 Phase 3, 28 recruiting
FAERS reports
3,562
2,260 serious, 264 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) and COLITIS Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Clindamycin Phosphate in Sodium Chloride Injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because Clindamycin Phosphate in Sodium Chloride Injection therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate [ see Indications and Usage ( 1 ) ] . It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin...
What it is approved for
From the label in effect Apr 28, 2026.
Clindamycin Phosphate in Sodium Chloride Injection contains clindamycin, a lincosamide antibacterial indicated for the treatment of the following in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: • Serious infections caused by susceptible anaerobic bacteria ( 1.1 ) • Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci. ( 1.2 ) • Lower Respiratory Tract Infections. ( 1.3 ) • Skin and Skin Structure Infections. ( 1.4 ) • Gynecological Infections. ( 1.5 ) • Intra-abdominal Infections. ( 1.6 ) • Septicemia. ( 1.7 ) • Bone and Joint Infections. ( 1.8 ) Limitation of use Since clindamycin does not diffuse adequately into the cerebrospinal fluid, Clindamycin Phosphate in Sodium Chloride Injection should not be used in the treatment of meningitis ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Phosphate in Sodium Chloride Injection and other antibacterial drugs, Clindamycin Phosphate in Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.10 ) 1.1 Infections Due to Susceptible Anaerobic Bacteria Clindamycin Phosphate in Sodium Chloride Injection is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Indications and Usage (1.3 - 1.7) ] . 1.2 Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci Clindamycin Phosphate in Sodium Chloride Injection is indicated for the treatment of serious infections due to susceptible isolates of streptococci, pneumococci, and...
Mechanism: Clindamycin is an antibacterial drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE · CLINDAMYCIN PHOSPHATE EQ 900MG BASE/50ML (EQ 18MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE · CLINDAMYCIN PHOSPHATE EQ 300MG BASE/50ML (EQ 6MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE · CLINDAMYCIN PHOSPHATE EQ 600MG BASE/50ML (EQ 12MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
University of OxfordAcademic, hospital or other
NCT04093765 · 5,542 participants · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Antimalarials · For: Plasmodium Falciparum Malaria
Sites: Mae Sot, Thailand
- Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT00642980 · 3,105 participants · Start Apr 2006 · Primary completion Jun 2011
Drug: Clindamycin; Placebo and 1 more · For: Pregnancy
Sites: Lille, France
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean InfectionPivotal-lookingCompleted
Alan TitaAcademic, hospital or other
NCT01235546 · 2,013 participants · Start May 2011 · Primary completion Dec 2015
Drug: Azithromycin and standard of care; Placebo and standard of care · For: Endometritis; Wound Infection; Abscess and 1 more
Sites: Birmingham, Alabama; New Orleans, Louisiana; Jackson, Mississippi · 9 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center TrialPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03283878 · 1,770 participants · Start Oct 24, 2017 · Primary completion Nov 20, 2024
Drug: Cefazolin · For: Arthropathy of Knee; Antibiotic Prophylaxis
Sites: San Francisco, California; Atlanta, Georgia; Towson, Maryland · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective373
- rash257
- drug hypersensitivity230
- off label use227
- diarrhoea190
- nausea186
- fatigue169
- pruritus168
- pain161
- condition aggravated135
- dyspnoea114
- headache113
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 48 |
| 2006 | 56 |
| 2007 | 14 |
| 2008 | 20 |
| 2009 | 43 |
| 2010 | 82 |
| 2011 | 65 |
| 2012 | 95 |
| 2013 | 101 |
| 2014 | 102 |
| 2015 | 124 |
| 2016 | 242 |
| 2017 | 182 |
| 2018 | 237 |
| 2019 | 276 |
| 2020 | 210 |
| 2021 | 194 |
| 2022 | 288 |
| 2023 | 305 |
| 2024 | 286 |
| 2025 | 309 |
| 2026 | 264 |
Recalls
1 FDA enforcement reports for this application.
Aug 6, 2026 · Class II · Ongoing
CGMP Deviations
Shortages
FDA's drug shortage list.
Current · updated Nov 3, 2026
Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50). Other
Current · updated Nov 18, 2026
Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50).
Current · updated Nov 18, 2026
Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antibiotic regimens for postpartum endometritis.
Mackeen AD, Packard RE, Ota E, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis.
Bartoszko JJ, Elias Z, Rudziak P, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T, Wilson C, Curtis N, et al. · Clin Infect Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.
Liu H, Yu H, Xia J, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials.
Kakpovbia EE, Young T, Milam EC, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review, Network Meta-Analysis
- Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis.
Wang W, Chen W, Liu Y, et al. · BMJ Open 2018 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.